When combined with MVA/rF-CEA/TRICOM, a cancer vaccine directed toward a self-antigen, cabozantinib increased the infiltration of lymphocytes, specifically CD8+ T cells, into the tumor microenvironment (Figure 4D and F). Here, CD8A is linked to cancer.